{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:28:53Z","timestamp":1794479333075,"version":"4.9.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.biopha.2026.119385","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T02:00:20Z","timestamp":1776564020000},"page":"119385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Inflammatory and immune-mediated toxicity of lipid nanoparticles"],"prefix":"10.1016","volume":"199","author":[{"given":"Soyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyukjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6081-0329","authenticated-orcid":false,"given":"Kyuri","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119385_bib1","series-title":"Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)","author":"Tarik Jasarevic","year":"2020"},{"issue":"5","key":"10.1016\/j.biopha.2026.119385_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"C.S. Grp, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119385_bib3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"F.P","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.biopha.2026.119385_bib4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2026.119385_bib5","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119385_bib6","first-page":"3481","volume":"30","author":"Huotari","year":"2011","journal-title":"Endosome Matura."},{"issue":"6","key":"10.1016\/j.biopha.2026.119385_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tips.2021.03.002","article-title":"The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA","volume":"42","author":"Patel","year":"2021","journal-title":"Trends Pharm. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119385_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","article-title":"Strategies to reduce the risks of mRNA drug and vaccine toxicity","volume":"23","author":"Bitounis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.biopha.2026.119385_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s42003-021-01728-8","article-title":"A high-throughput Galectin-9 imaging assay for quantifying nanoparticle uptake, endosomal escape and functional RNA delivery","volume":"4","author":"Munson","year":"2021","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119385_bib11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acschembio.0c00003","article-title":"Engineering Caveolae-Targeted Lipid Nanoparticles To Deliver mRNA to the Lungs","volume":"15","author":"Li","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119385_bib12","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2147\/IJN.S363990","article-title":"Optimization of Lipid Nanoformulations for Effective mRNA Delivery","volume":"17","author":"Chen","year":"2022","journal-title":"Int J. Nanomed."},{"issue":"11","key":"10.1016\/j.biopha.2026.119385_bib13","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1007\/s13346-023-01362-3","article-title":"Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy","volume":"13","author":"Dogbey","year":"2023","journal-title":"Drug Deliv. Transl. Re"},{"issue":"2","key":"10.1016\/j.biopha.2026.119385_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41587-019-0402-x","article-title":"Emerging patent landscape for non-viral vectors used for gene therapy","volume":"38","author":"Pican\u00e7o-Castro","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119385_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020","volume":"70","author":"Shimabukuro","year":"2021","journal-title":"Mmwr-Morb. Mortal. W"},{"issue":"4","key":"10.1016\/j.biopha.2026.119385_bib16","first-page":"1423","article-title":"mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J. Aller Cl. Imm-Pr."},{"key":"10.1016\/j.biopha.2026.119385_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1336906","article-title":"The mRNA-LNP vaccines\u2013the good, the bad and the ugly?","volume":"15","author":"Igy\u00e1rt\u00f3","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119385_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control Release"},{"issue":"11","key":"10.1016\/j.biopha.2026.119385_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Del."},{"issue":"10","key":"10.1016\/j.biopha.2026.119385_bib20","article-title":"Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccin. (Basel)"},{"issue":"7","key":"10.1016\/j.biopha.2026.119385_bib21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.biopha.2026.119385_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2021.12.027","article-title":"Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)","volume":"344","author":"Parhiz","year":"2022","journal-title":"J. Control Release"},{"issue":"6","key":"10.1016\/j.biopha.2026.119385_bib23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin. Exp. Allergy"},{"issue":"3","key":"10.1016\/j.biopha.2026.119385_bib24","article-title":"Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines","volume":"11","author":"Swetha","year":"2023","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.biopha.2026.119385_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2024.172240","article-title":"Impact of physicochemical properties on biological effects of lipid nanoparticles: Are they completely safe","volume":"927","author":"Yuan","year":"2024","journal-title":"Sci. Total Environ."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"Npj Vaccin."},{"issue":"11","key":"10.1016\/j.biopha.2026.119385_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d","volume":"8","author":"Chaudhary","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.biopha.2026.119385_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020181","article-title":"The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles","volume":"16","author":"Anindita","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"Npj Vaccin."},{"issue":"11","key":"10.1016\/j.biopha.2026.119385_bib30","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","article-title":"Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery","volume":"3","author":"Nogueira","year":"2020","journal-title":"Acs Appl. Nano Mater."},{"issue":"26","key":"10.1016\/j.biopha.2026.119385_bib31","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.biopha.2026.119385_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.biopha.2026.119385_bib33","first-page":"1533","article-title":"Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J. Aller Cl. Imm-Pr."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"Npj Vaccin."},{"key":"10.1016\/j.biopha.2026.119385_bib35","doi-asserted-by":"crossref","DOI":"10.34133\/bmr.0017","article-title":"Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics","volume":"28","author":"Lee","year":"2024","journal-title":"Biomater. Res"},{"key":"10.1016\/j.biopha.2026.119385_bib36","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine","author":"Ju","year":"2022","journal-title":"Acs Nano"},{"issue":"21","key":"10.1016\/j.biopha.2026.119385_bib37","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"6","key":"10.1016\/j.biopha.2026.119385_bib39","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1021\/acsnano.2c12193","article-title":"Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.biopha.2026.119385_bib40","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"Acs Nano"},{"issue":"12","key":"10.1016\/j.biopha.2026.119385_bib41","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1039\/D2BM01846B","article-title":"Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury","volume":"11","author":"Waggoner","year":"2023","journal-title":"Biomater. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119385_bib42","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1016\/j.ymthe.2022.07.007","article-title":"mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells","volume":"30","author":"Bevers","year":"2022","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119385_bib43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1039\/D1BM01454D","article-title":"Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)","volume":"10","author":"Alvarez-Benedicto","year":"2022","journal-title":"Biomater. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2026.119385_bib44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.biopha.2026.119385_bib45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.biopha.2026.119385_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103049","article-title":"Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics","volume":"85","author":"Chen","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119385_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.freeradbiomed.2016.12.034","article-title":"Pleiotropic effects of oxidized phospholipids","volume":"111","author":"Bochkov","year":"2017","journal-title":"Free Radic. Biol. Med"},{"issue":"5","key":"10.1016\/j.biopha.2026.119385_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41577-021-00618-8","article-title":"Innate immune detection of lipid oxidation as a threat assessment strategy","volume":"22","author":"Zhivaki","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119385_bib49","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3389\/fimmu.2019.02927","article-title":"Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells","volume":"10","author":"Correa","year":"2019","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119385_bib50","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1172\/JCI115932","article-title":"Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells","volume":"90","author":"Kume","year":"1992","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119385_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omtm.2023.06.005","article-title":"Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues","volume":"30","author":"Chander","year":"2023","journal-title":"Mol. Ther. -Meth Clin. D."},{"key":"10.1016\/j.biopha.2026.119385_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119385_bib53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.freeradbiomed.2017.04.013","article-title":"Cholesterol and related sterols autoxidation","volume":"111","author":"Zerbinati","year":"2017","journal-title":"Free Radic. Biol. Med"},{"issue":"42","key":"10.1016\/j.biopha.2026.119385_bib54","doi-asserted-by":"crossref","first-page":"28480","DOI":"10.1021\/acsnano.4c06369","article-title":"Immune Implications of Cholesterol-Containing Lipid Nanoparticles","volume":"18","author":"Back","year":"2024","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.biopha.2026.119385_bib55","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.cmet.2021.09.001","article-title":"Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases","volume":"33","author":"Song","year":"2021","journal-title":"Cell Metab."},{"issue":"7293","key":"10.1016\/j.biopha.2026.119385_bib56","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2026.119385_bib57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","article-title":"Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size","volume":"39","author":"Di","year":"2022","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2026.119385_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control Release"},{"issue":"8","key":"10.1016\/j.biopha.2026.119385_bib61","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1369\/0022155411410885","article-title":"Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery","volume":"59","author":"Shi","year":"2011","journal-title":"J. Histochem Cytochem"},{"issue":"2","key":"10.1016\/j.biopha.2026.119385_bib62","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00204-024-03912-1","article-title":"Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model","volume":"99","author":"Ahn","year":"2025","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2026.119385_bib63","series-title":"Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry","author":"FDA","year":"2022"},{"key":"10.1016\/j.biopha.2026.119385_bib64","series-title":"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation: Guidance for Industry","author":"FDA","year":"2018"},{"key":"10.1016\/j.biopha.2026.119385_bib65","series-title":"Immunogenicity Assessment for Therapeutic Protein Products: Guidance for Industry","author":"FDA","year":"2014"},{"issue":"3","key":"10.1016\/j.biopha.2026.119385_bib66","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1601399","article-title":"Type II NKT Cells and Their Emerging Role in Health and Disease","volume":"198","author":"Dhodapkar","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119385_bib67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1189\/JLB.0309135","article-title":"Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases","volume":"86","author":"Gao","year":"2009","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0300985815591076","article-title":"Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies","volume":"53","author":"Sharapova","year":"2016","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.biopha.2026.119385_bib69","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control Release"},{"issue":"7","key":"10.1016\/j.biopha.2026.119385_bib70","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119385_bib71","first-page":"486","article-title":"A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety","volume":"38","author":"Bae","year":"2024","journal-title":"Bioact. Mater."},{"issue":"7","key":"10.1016\/j.biopha.2026.119385_bib72","article-title":"Novel Less Toxic, Lymphoid Tissue-Targeted Lipid Nanoparticles Containing a Vitamin B5-Derived Ionizable Lipid for mRNA Vaccine Delivery","volume":"14","author":"Yoo","year":"2025","journal-title":"Adv. Health Mater."},{"issue":"9","key":"10.1016\/j.biopha.2026.119385_bib73","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119385_bib74","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119385_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1383038","article-title":"Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation","volume":"4","author":"van Zyl","year":"2024","journal-title":"Front Drug Deliv."},{"key":"10.1016\/j.biopha.2026.119385_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2023.07.031","article-title":"Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery","volume":"361","author":"Berger","year":"2023","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.biopha.2026.119385_bib77","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.146.12.4234","article-title":"The Role of Surface-Charge in the Activation of the Classical and Alternative Pathways of Complement by Liposomes","volume":"146","author":"Chonn","year":"1991","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119385_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/nano10040787","article-title":"Stealth coating of nanoparticles in drug-delivery systems","volume":"10","author":"Fam","year":"2020","journal-title":"Nanomaterials"},{"issue":"5","key":"10.1016\/j.biopha.2026.119385_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001643","article-title":"Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes","volume":"20","author":"Syenina","year":"2022","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib80","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1038\/s41467-024-53914-x","article-title":"Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib81","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1038\/s41467-024-51056-8","article-title":"Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy","volume":"15","author":"Bai","year":"2024","journal-title":"Nat. Commun."},{"issue":"45","key":"10.1016\/j.biopha.2026.119385_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202404684","article-title":"Discovery of Ketal-Ester Ionizable Lipid Nanoparticle with Reduced Hepatotoxicity, Enhanced Spleen Tropism for mRNA Vaccine Delivery","volume":"11","author":"Lv","year":"2024","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119385_bib83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2144\/000113450","article-title":"Design of an in vivo cleavable disulfide linker in recombinant fusion proteins","volume":"49","author":"Chen","year":"2010","journal-title":"Biotechniques"},{"issue":"41","key":"10.1016\/j.biopha.2026.119385_bib84","doi-asserted-by":"crossref","first-page":"37411","DOI":"10.1021\/acsami.9b08901","article-title":"Thioether Phosphatidylcholine Liposomes: A Novel ROS-Responsive Platform for Drug Delivery","volume":"11","author":"Du","year":"2019","journal-title":"Acs Appl. Mater. Inter"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:42:50Z","timestamp":1794476570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226004208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":84,"alternative-id":["S0753332226004208"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119385","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory and immune-mediated toxicity of lipid nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119385"}}